procarbazine has been researched along with Lymphoma, Follicular in 21 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Lymphoma, Follicular: Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-five patients with Stage I to III follicular lymphoma were randomized." | 2.71 | A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma. ( Cabanillas, F; Cox, JD; Ha, CS; Lee, MS; McLaughlin, P; Mesina, OM; Rodriguez, MA; Romaguera, JE; Tucker, SL; Younes, A, 2005) |
| "The best treatment of follicular lymphoma remains to be determined because the long natural history of follicular lymphoma requires mature data for accurate analysis." | 2.70 | Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma. ( Avilés, A; Cleto, S; Díaz, N; Díaz-Maqueo, JC; García, EL; Neri, N; Talavera, A, 2001) |
| "We reviewed all reported cases of Burkitt's lymphoma and/or Burkitt's leukemia (BLL) occurring following therapy for Hodgkin's disease." | 2.39 | Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. ( Cooper, DL; Levy, A; Salloum, E; Tallini, G, 1996) |
| "The natural history of follicular lymphoma is believed not to have changed over the last 30 years." | 1.33 | New treatment options have changed the survival of patients with follicular lymphoma. ( Fisher, RI; LeBlanc, M; Maloney, DG; Miller, TP; Press, OW; Unger, JM, 2005) |
| "Grade 3 follicular lymphoma (FL3) is thought to have an aggressive clinical course." | 1.32 | A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. ( Aoun, P; Armitage, JO; Bierman, PJ; Bociek, RG; Chan, WC; Greiner, TC; Hans, CP; Hock, LM; Lynch, JC; Vose, JM; Weisenburger, DD, 2003) |
| "The incidence of follicular lymphoma in Japan is far lower than that in western countries, and no large-scale clinicopathologic studies on this neoplasm have been conducted in Japan." | 1.29 | Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan. ( Fukushima, T; Ikeda, H; Katsumata, N; Kobayashi, Y; Matsuno, Y; Nakata, M; Nakayama, H; Narabayashi, M; Tajima, K; Takenaka, T; Takeyama, K; Tobinai, K; Yokozawa, T, 1996) |
| "For patients with lymphosarcoma the average duration of complete remission was 26." | 1.26 | [Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)]. ( Hiller, E; Schmülling, RM; Tigges, FJ; Waller, HD; Wilms, K, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (28.57) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Régis, A | 1 |
| Ben Salem, D | 1 |
| Lambert, A | 1 |
| Couaillier, JF | 1 |
| Casasnovas, O | 1 |
| Piard, F | 1 |
| Krausé, D | 1 |
| Uchida, T | 1 |
| Sugimoto, K | 1 |
| Koike, M | 1 |
| Janikova, A | 1 |
| Koristek, Z | 1 |
| Vinklarkova, J | 1 |
| Pavlik, T | 1 |
| Sticha, M | 1 |
| Navratil, M | 1 |
| Kral, Z | 1 |
| Vasova, I | 1 |
| Mayer, J | 1 |
| Irie, E | 1 |
| Shirota, Y | 1 |
| Suzuki, C | 1 |
| Tajima, Y | 1 |
| Ishizawa, K | 1 |
| Kameoka, J | 1 |
| Harigae, H | 1 |
| Ishii, T | 1 |
| Hans, CP | 1 |
| Weisenburger, DD | 1 |
| Vose, JM | 1 |
| Hock, LM | 1 |
| Lynch, JC | 1 |
| Aoun, P | 1 |
| Greiner, TC | 1 |
| Chan, WC | 1 |
| Bociek, RG | 1 |
| Bierman, PJ | 1 |
| Armitage, JO | 1 |
| TODD, ID | 1 |
| Ha, CS | 1 |
| Cabanillas, F | 1 |
| Lee, MS | 1 |
| Tucker, SL | 1 |
| McLaughlin, P | 1 |
| Rodriguez, MA | 1 |
| Younes, A | 1 |
| Romaguera, JE | 1 |
| Mesina, OM | 1 |
| Cox, JD | 1 |
| Fisher, RI | 2 |
| LeBlanc, M | 1 |
| Press, OW | 1 |
| Maloney, DG | 1 |
| Unger, JM | 1 |
| Miller, TP | 1 |
| Kober, T | 1 |
| Hülsewede, H | 1 |
| Bohlius, J | 1 |
| Engert, A | 1 |
| Portlock, CS | 2 |
| Longo, DL | 1 |
| Young, RC | 1 |
| Hubbard, SM | 1 |
| Wesley, M | 1 |
| Jaffe, E | 1 |
| Berard, C | 1 |
| DeVita, VT | 1 |
| Jurcic, JG | 1 |
| Koll, B | 1 |
| Brown, AE | 1 |
| Crown, JP | 1 |
| Yahalom, J | 1 |
| Gulati, SC | 1 |
| Salloum, E | 1 |
| Tallini, G | 1 |
| Levy, A | 1 |
| Cooper, DL | 1 |
| Katsumata, N | 1 |
| Matsuno, Y | 1 |
| Nakayama, H | 1 |
| Takenaka, T | 1 |
| Kobayashi, Y | 1 |
| Takeyama, K | 1 |
| Narabayashi, M | 1 |
| Fukushima, T | 1 |
| Yokozawa, T | 1 |
| Nakata, M | 1 |
| Tajima, K | 1 |
| Ikeda, H | 1 |
| Tobinai, K | 1 |
| Davidge-Pitts, M | 1 |
| Dansey, R | 1 |
| Bezwoda, WR | 1 |
| Niitsu, N | 1 |
| Umeda, M | 1 |
| Neri, N | 1 |
| Avilés, A | 1 |
| Cleto, S | 1 |
| Díaz, N | 1 |
| Talavera, A | 1 |
| García, EL | 1 |
| Díaz-Maqueo, JC | 1 |
| Tigges, FJ | 1 |
| Schmülling, RM | 1 |
| Hiller, E | 1 |
| Waller, HD | 1 |
| Wilms, K | 1 |
| Solal-Céligny, P | 1 |
| Fairley, GH | 1 |
| Freeman, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma[NCT02008006] | Phase 2 | 21 participants (Actual) | Interventional | 2014-07-09 | Terminated (stopped due to Insufficient recruitment and unavailability of the treatment) | ||
| Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response[NCT04508647] | Phase 2 | 4 participants (Actual) | Interventional | 2020-11-23 | Completed | ||
| A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas[NCT00003784] | Phase 2 | 102 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of subjects that reached a complete response at the end of single agent induction as defined by a Lugano score of 3 or less on arm MONO - Monotherapy: Ublituximab.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake.~Patients who did not reach complete response at this point were then bridged to arm COMBO - Combotherapy: Ublituximab + Umbralisib." (NCT04508647)
Timeframe: 8 weeks post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
"Number of subjects that reached a complete response at up to 12 months post induction as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Complete response assessed via PET CT scan utilizing the Lugano-Deauville Criteria where none of the lymphoma lesions had FDG ( FluoroDeoxyglucose) avidity greater than the liver uptake." (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
"Overall Response Rate for number of subjects as defined by a Lugano score of 3 or less on arms MONO - Monotherapy: Ublituximab.OR Combotherapy: Ublituximab + Umbralisib.~Overall response rate assessed via PET CT utilizing Lugano deauvile criteria where lymphoma lesions had responded and would include complete response, partial response (> 50% improvement) and stable disease (less than 50 % response)" (NCT04508647)
Timeframe: up to 12 months post induction
| Intervention | Participants (Count of Participants) |
|---|---|
| Ublituximab Only | 2 |
| Ublituximab First, Then Ublituximab and Umbralisib | 2 |
3 reviews available for procarbazine and Lymphoma, Follicular
| Article | Year |
|---|---|
Fourth biannual report of the Cochrane Haematological Malignancies Group.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2006 |
Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Burkitt Lymphoma; Cyclophosphamide | 1996 |
[Follicular lymphomas. Therapeutic indications].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorub | 1992 |
3 trials available for procarbazine and Lymphoma, Follicular
| Article | Year |
|---|---|
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; | 2005 |
[Prognostic factors of follicular lymphoma treated with combination chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1997 |
Chemotherapy plus interferon-alpha2b versus chemotherapy in the treatment of follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dr | 2001 |
15 other studies available for procarbazine and Lymphoma, Follicular
| Article | Year |
|---|---|
[Concomitant pulmonary Langerhans cell histiocytosis and malignant lymphoma: report of two cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Combined Modality Therapy; | 2009 |
[Composite lymphoma consisting of Hodgkin lymphoma and follicular lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Groin; Hodgkin Disease; Humans; Ly | 2009 |
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antine | 2009 |
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.
Topics: Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic C | 2010 |
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomyci | 2003 |
NATULAN IN MANAGEMENT OF LATE HODGKIN'S DISEASE, OTHER LYMPHORETICULAR NEOPLASMS, AND MALIGNANT MELANOMA.
Topics: Antineoplastic Agents; Drug Therapy; Hodgkin Disease; Humans; Hydrazines; Lymphoma; Lymphoma, Follic | 1965 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
New treatment options have changed the survival of patients with follicular lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemothe | 2005 |
Management of the indolent non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati | 1980 |
Prolonged initial remission in patients with nodular mixed lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Deferral of initial therapy for advanced indolent lymphomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Therap | 1982 |
Excretion of Ascaris lumbricoides during total body irradiation.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascariasis; Ascaris lumbricoides; Bo | 1994 |
Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 1996 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cycl | 1997 |
[Polychemotherapy in non-hodgkin lymphoma with a modified MOPP scheme (author's transl)].
Topics: Adult; Cyclophosphamide; Female; Humans; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Dif | 1977 |
Blood and neoplastic diseases. Treatment of the lymphomas.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follicular; Ne | 1974 |